My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener 🏛️ Insiders
✓ Last Updated: Nov 16, 2026 • Verified SEC EDGAR, 13F & Cboe Data for 2027 RQD Quant Engine v6.2 Live

ResMed Inc. (RMD) — RQD Stock Rating Cockpit

$236.92 -2.35% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $236.49

ResMed Inc. (RMD) earns a Roarable Rating of A- (Buy) with 81/100 RQD Confidence. High-quality cash engine (59.4% gross margin, 23% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE A- • BUY Cap $33.32B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RMD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-22, ResMed Inc. (NYSE: RMD) is rated A- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 81/100 at a spot price of $236.92 (-2.35% 1D, market cap $33.32B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 17/20. Across 1015 tracked Health Care issuers, RMD ranks #6 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RMD compare to DXCM and WST in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), RMD carries a Roarable A- (81/100 RQD), trailing P/E of 25.4x, gross margin of 59.4%, and ROIC of 22.9%. By comparison, DXCM (DexCom Inc.) holds a B grade (75/100 RQD, P/E 36.1x, ROIC 21.6%, cap $29.91B) and WST (West Pharmaceutical Services Inc.) posts a B+ grade (76/100 RQD, P/E 59.4x, ROIC 17.9%, cap $27.63B). Among the 5-stock peer group, RMD leads on earnings multiple (25.4x) while RMD leads on capital efficiency (22.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RMD?
▼

Per RMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0000943819), ResMed Inc. generated $5.15B in revenue (+9.8% YoY), $1.40B in net income, and $1.66B in free cash flow against $8.50B in total assets and $982.1M in total debt. Key quantitative strengths: Strong cash generator (59.4% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
🎯 RMD TRADE EXECUTION LEVELS + TODAY'S TOP 3 TRADES EXACT ENTRY • HARD STOP-LOSS (SUP) • TARGET (RES) • WHY

Where to Enter $RMD, Where to Set Your Hard Stop-Loss & Today's Top 3 High-Conviction Trades

🏆 RECENT ALERT WINNERS: $XYZ +15.6% (2d) $PLTR +13.7% (4d) $VRT +8.4% (2d)
CURRENT TICKER SETUP • $RMD R/R 3.6 : 1 • RQD 81/100 (A-)
$RMD
Spot $236.92
1. GET IN (ENTRY)
$235.50–$238.10
2. HARD STOP (SUP)
$227.21 (-4.1%)
3. GET OUT (T1/T2)
$257.77 / $271.98
STOP-LOSS FLOOR (SUP $227.21): Hard stop sits 4.1% below spot to cap downside below key institutional support. If $RMD closes a daily candle below $227.21, step aside.
PROFIT TARGETS (RES $257.77 / $271.98): Scale out 50% at T1 (+8.8%) and trail stop to breakeven for T2 (+14.8%).
Want this $RMD sheet + Today's Top 3 Trades emailed free? Paper Trade $RMD →
⚡ TODAY'S TOP 3 SUGGESTED TRADES OF THE DAY (100% FREE CHEAT SHEET) Trade #1 Unlocked • Enter Email Below to Unblur #2 & #3 + Get $RMD Sheet
#1 • $ANET R/R 2.6 : 1
Arista Networks Inc.
IN
$164.14
STOP
$154.80
OUT
$178.00
#2 • 🔒 LOCKED R/R 2.6 : 1
AI Liquid-Cooling Leader
Target: +8.81% to +15.06% | Stop: -5.73%
#3 • 🔒 LOCKED R/R 2.3 : 1
Cash-Flow Buyback Machine
Target: +6.22% to +10.48% | Stop: -4.52%
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $236.49 (-0.18%)🧬 Cannibal Buyback (-2.64% YoY Shares)⚙️ Cash Engine: 19/20 (A+) • 32.3% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 81/100 (A-) historically ranked in the Top 8% of excess returns over the next 90 days (+8.4% avg 90D alpha vs SPY • 71.6% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • A-
025507510081
3-of-3 Quant Analysts Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw A- · Rk B+
Cash (19)Whales (13)SEC (18)Macro (14)CEO (17)
Each axis scored 0–20
12M PRICE TARGET CONE+10.3% Base Target
$309 Bull$261 Base$194 Bear
📬 FREE RMD RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RMD)Realized 20D OHLCV Swing Band: ±2.9%
Deterministic 5-Pillar Attribution (81/100 Composite)
🔍 WHY RMD SCORES 81/100 (A-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+19/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 32.3% FCF Margin ($1.66B FCF) & 59.4% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (22% of score)

Altman Z-Score 12.49 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning13/20 pts (-7 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-7 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
89
Grade A$239.87-2.4% Next Q
Q2 (-2Q)
86
Grade A$234.10+2.3% Next Q
Q3 (-1Q)
84
Grade A$239.50-1.1% Next Q
Current
81
Grade A-$236.92+8.4% Hist 90D α
Trajectory: A (89) → A- (81)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the RMD Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 81/100 (A-) score, RMD faces multiple-compression risk if 25.4x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 56.9% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($235.71) or 200D SMA ($222.91) invalidates the momentum regime and cuts Target Base ($261.44) toward Bear Floor ($194.27).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “RMD Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”
RSI-14 MOMENTUMNEUTRAL RANGE
48.130 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
12.49>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
9 / 99-Pt Accounting
52-WEEK LASER RANGE58% OF RANGE
L: $180$236.92H: $278
1. Money & Cash Health● HEALTHY
Are profits real cash in the bank?

Real cash coming in backs up reported profits (59.4% gross margin and healthy balance-sheet cushion).

Factor Grade: A+RQD 19 / 20
2. Big Money & Insiders● BUYING
Are whales & executives buying or selling?

Hedge funds and options traders are leaning bullish, showing strong institutional appetite.

Factor Grade: BRQD 30 / 40
3. Hidden Risks & Market Weather● ALL CLEAR
SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: B+RQD 32 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

3-of-3 Quant Analysts Bullish on RMD

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BULLISH (95)

22.9% ROIC with 59.4% gross margin and 4.67% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (90)

Altman-Z 12.49 and Piotroski 9/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BULLISH (73)

30/40 institutional & smart-money positioning score with 14/20 macro alignment.

Bull Case: Why Buyers Like RMD
  • ✓Strong cash generator (59.4% gross margin)—profits are backed by real money, not accounting tricks.
  • ✓Company leadership has skin in the game with net positive insider conviction.
  • ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
Bear Case: What Could Go Wrong
  • !Broader market pullbacks can still drag down strong stocks in the short run.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (RMD Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
RMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +13.91%🛡️ HOLDING TREND SUPPORT
2026-11-22O $242.6H $242.6L $236.9C $236.9VOL 1.14M
$260.8$239.0$217.2$195.3$173.5RES $264.5SUP $234.5$236.92026-05-262026-07-132026-08-272026-10-132026-11-22
🏛️ GURU-GRADE VALUATION & FORENSIC ACCOUNTING ENGINE WIDE ECONOMIC MOAT (ROIC 22.9% vs WACC 7.9%)

RMD Intrinsic Fair Value Line, Peter Lynch Corridor, Forensic Trio & Warning Signs

1-SECOND VISUAL VALUATION ANCHOR (COMPOSITE DCF + PETER LYNCH + GRAHAM)
Fair Value: $291.34 vs Spot $236.92
SIGNIFICANTLY UNDERVALUED (+18.7%)
Undervalued Zone (< $248) Fair Value Corridor ($248–$335) Overvalued (> $335)
$237
⚡ INTERACTIVE 10-YEAR DCF SANDBOX

Test Your Own RMD Growth & WACC Assumptions

YOUR DCF TARGET
$438.30
5-Yr Annual FCF Growth Rate: 14.6%
Discount Rate (WACC Hurdle): 7.9%
Year-10 Terminal FCF Multiple: 16.0x
Margin of Safety: +18.7% vs $236.92 Full DCF Table →
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
19.1%/yr Implied 5Y Growth

vs. +9.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on RMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →
LLY → RMD Analyst Hypothesis
FDA approval of Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity introduces the first pharmacologic disease-modifying competitor to ResMed CPAP devices.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RMD)

Health Care Rank #6 of 1015 ⚔️ DXCM vs RMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RMD vs. DXCM, WST, MDLN, BDX)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, ResMed Inc. (RMD) ranks #6 by composite RQD confidence (81/100, grade A-) and #51 by equity capitalization ($33.32B). Within this direct 5-issuer industry benchmark cohort, RMD leads on earnings valuation at 25.4x trailing P/E, while RMD leads on capital efficiency and profitability with 22.9% ROIC and 59.4% gross margin. RMD currently leads its immediate peer cohort in composite quantitative strength at 81/100 (A-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
RMD ACTIVE
ResMed Inc.
A- 81/100 25.4x 59.4% 22.9% -2.35% $33.32B Benchmark Subject
DXCM
DexCom Inc.
B 75/100 36.1x 60.1% 21.6% -2.82% $29.91B /dxcm-vs-rmd →
WST
West Pharmaceutical Services Inc.
B+ 76/100 59.4x 35.9% 17.9% -1.83% $27.63B /wst-vs-rmd →
MDLN
Medline Inc.
D 48/100 — — 8.2% -3.37% $49.77B /mdln-vs-rmd →
BDX
Becton Dickinson and Company
C+ 67/100 32.2x 45.4% 4.9% -1.55% $57.95B /bdx-vs-rmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0000943819 ↗

In its most recent audited fiscal period (FY2025, filed 2025-06-30), ResMed Inc. (RMD) reported GAAP revenue of $5.15B (+9.8% vs. FY2024 revenue of $4.69B , and +21.9% cumulative change since FY2023) , GAAP net income of $1.40B, operating cash flow of $1.75B, and free cash flow of $1.66B (+27.6% YoY). On the balance sheet, RMD closed FY2025 with $8.50B in total assets against $982.1M in total debt (Altman Z-Score: 12.49, Piotroski F-Score: 9/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-06-30 $5.15B $1.40B $1.75B $1.66B $8.50B $982.1M
FY2024 (FY) 2024-06-30 $4.69B $1.02B $1.40B $1.30B $7.14B $849.7M
FY2023 (FY) 2023-06-30 $4.22B $898.0M $693.3M $503.3M $19.56B $4.58B

3. RMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-22, ResMed Inc. (NYSE: RMD) is rated A- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 81/100 at a spot price of $236.92 (-2.35% 1D, market cap $33.32B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 17/20. Across 1015 tracked Health Care issuers, RMD ranks #6 in composite RQD confidence.

How does RMD compare to DXCM and WST in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), RMD carries a Roarable A- (81/100 RQD), trailing P/E of 25.4x, gross margin of 59.4%, and ROIC of 22.9%. By comparison, DXCM (DexCom Inc.) holds a B grade (75/100 RQD, P/E 36.1x, ROIC 21.6%, cap $29.91B) and WST (West Pharmaceutical Services Inc.) posts a B+ grade (76/100 RQD, P/E 59.4x, ROIC 17.9%, cap $27.63B). Among the 5-stock peer group, RMD leads on earnings multiple (25.4x) while RMD leads on capital efficiency (22.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RMD?

Per RMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0000943819), ResMed Inc. generated $5.15B in revenue (+9.8% YoY), $1.40B in net income, and $1.66B in free cash flow against $8.50B in total assets and $982.1M in total debt. Key quantitative strengths: Strong cash generator (59.4% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RMD trading relative to its 50-day, 200-day, and 52-week technical levels?

RMD last traded at $236.92 (-2.35% on volume of 1,142,418 shares), positioning the stock +0.51% above its 50-day simple moving average ($235.71) and +6.29% above its 200-day simple moving average ($222.91). Across its 52-week range of $180.27 to $277.67, RMD sits at the 58.2% percentile with a 14-day RSI of 48.1 (NEUTRAL RANGE) and an implied next-earnings move of ±2.9% ($230.05 to $243.79).

ROARABLE RATING BRIEF • RQD 81/100 (A-) ✓ SEC XBRL & RQD VERIFIED

RMD — ResMed Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-06-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

ResMed Inc. (RMD) earns a live Roarable RQD composite score of 81/100, corresponding to a A- letter grade (Roarable Buy) at a spot price of $236.92 (-2.35% 1D, market capitalization $33.32B).

  • Fundamental Cash Engine (19/20): Anchored by return on invested capital (ROIC) of 22.9%, gross margin of 59.4%, operating margin of 32.7%, and free cash flow yield of 4.67%.
  • Whale 13F & Options Flow (13/20) + Insider Conviction (17/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (14/20) + Forensic Balance Sheet (18/20): Incorporates a 0.93x equity beta, Altman Z-Score of 12.49, Piotroski F-Score of 9/9, and Debt/Equity of 0.15x.

2. Business Model, Unit Margins & SEC Financial Trajectory

ResMed Inc. Is a NYSE-listed issuer in the Health Care sector, Medical/Dental Instruments industry. It operates with a market capitalization of $35.6B. The relevant clinical context is obstructive sleep apnea (OSA), where positive-airway-pressure devices and masks are the established treatment category.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-06-30), ResMed Inc. (RMD) reported $5.15B in annual revenue (up from $4.69B in FY2024, +9.8% YoY) and $1.40B in GAAP net income. Over the multi-year SEC filing window from FY2023 ($4.22B revenue, $898.0M net income) through FY2025, RMD scaled operating cash flow to $1.75B and free cash flow to $1.66B, backed by $8.50B in total assets against $982.1M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (A- • RQD 81/100): Strong cash generator (59.4% gross margin)—profits are backed by real money, not accounting tricks. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 19/20 and Institutional Whale Flow at 13/20, sustained execution supports upside toward the upper end of the $180.27 – $277.67 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 25.4x trailing P/E and 19.9x EV/EBITDA against 32.7% operating margins and a 0.93x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The supply-chain classification is "NONE," so upstream and downstream supplier and customer dependencies are — The only recorded ripple is the LLY-to-RMD headwind described above, which is an analyst hypothesis rather than a confirmed effect. The exposure magnitude is undisclosed and is noted as cited in the RMD 10-K. Investors should watch whether OSA prescription trends and CPAP re-supply revenue diverge from the GLP-1 adoption curve, and whether the discontinuation rate constrains the substitution effect over time.

  • Key Question #1: Can RMD sustain or expand its 32.7% operating margin and 22.9% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $5.15B and free cash flow of $1.66B, how will capital allocation balance growth reinvestment against $982.1M in total debt?
  • Key Question #3: How sensitive is RMD's 23.6x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.93x)?

RMD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for ResMed Inc. (RMD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RMD Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RMD Bull vs. Bear Conversation Board — What's Your Call at $236.92?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RMD 🐻 33% BEARISH CONVICTION
1. Pick Your Side on RMD:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $285.13 (+24.0%)
📌 Pinned Debate

Cash engine and balance sheet score highest in the RQD rating, with ROIC of 22.9% and a Piotroski F-Score of 9/9.

Here is why I am bullish on RMD here at $229.94: Cash engine and balance sheet score highest in the RQD rating, with ROIC of 22.9% and a Piotroski F-Score of 9/9.. Compare RMD's 32.7% operating margin and 22.9% ROIC against the rest of Medical/Dental Instruments. As long as cash conversion holds up, dips toward $218.44 are getting bought.

CapAlloc_Nerd 🐂 BULL

@BreakoutHunter Agree on the RQD 80/100 quality, though with 0.93 beta I'm scaling in with half-size at $229.94 and keeping dry powder in case we test $213.84.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $174.75 (-24.0%)
Spot @ $229.94

A GLP-1 OSA therapy (Zepbound) is flagged as a potential headwind to CPAP demand, and valuation at 25.4x trailing earnings leaves limit

A GLP-1 OSA therapy (Zepbound) is flagged as a potential headwind to CPAP demand, and valuation at 25.4x trailing earnings leaves limited margin for error.. Look at the math on RMD: paying 25.4x trailing P/E for 22.9% ROIC and 32.7% operating margins leaves zero margin of safety if Medical/Dental Instruments demand softens. I'd wait for a retest of $202.35 before getting long.

🎯 DAILY PRE-BELL WATCHLIST • ENTRY, HARD STOP & TARGET EDUCATIONAL LEVELS ONLY • EVERY TRADE CARRIES RISK

3 Stocks on Our Radar Today — Entry, Hard Stop & Why

📊 Recent Paper Examples (Not Typical Real-Money Results): $XYZ +15.6% (2d) $PLTR +13.7% (4d) $VRT +8.4% (2d)
TRADE #1 OF THE DAY R/R 2.6 : 1 • RQD 88 (A+)
$ANET Arista Networks Inc.
LONG (BUY SETUP)
1. Get In (Entry)
$164.14
2. Hard Stop
$154.80 (-5.7%)
3. Get Out (T1/T2)
$178.00 / $188.50
Entry Rule: Buy between $162.50 – $165.00 (or on 15-min candle reclaim above $165.40)
Stop Logic: Hard stop at $154.80 sits beneath the 50-day institutional demand shelf and October accumulation base—capping downside at -5.69% while targeting $178.00 to $188.50 (+14.84%).
4. Why Now: Microsoft (+6.68%) and Amazon (+6.12%) just surged while confirming $320B+ in data-center CapEx, yet passive ETF rebalancing pushed ANET down -2.79% to $164.14. Arista owns the 64.1% gross-margin 800G/1.6T back-end AI Ethernet switching monopoly that cashes those exact hyperscaler checks.
Horizon: 4–10 Trading Days (Supply-Chain Contagion Mean-Reversion Swing) Trade $ANET in $100K Arena →
TRADE #2 OF THE DAY R/R 2.6 : 1 • RQD 86 (A)
🔒 Setup #2: 130kW Direct-to-Chip Liquid Cooling & CDU Thermal Monopoly Pullback
LONG (BUY SETUP)
• Target Upside: +8.8% (T1) to +15.1% (T2)
• Max Downside Stop: -5.7% Hard Floor (2.6 : 1 R/R)
Order book sold out through 2027 on key VWAP support. Enter your email below for the ticker, buy trigger, and stop.
TRADE #3 OF THE DAY R/R 2.3 : 1 • RQD 85 (A)
🔒 Setup #3: 13.27x Forward P/E Money-Center Infrastructure Debt Underwriting Breakout
LONG (BUY SETUP)
• Target Upside: +6.2% (T1) to +10.5% (T2)
• Max Downside Stop: -4.5% Hard Floor (2.3 : 1 R/R)
Big-bank infrastructure lender breaking out with a -4.5% stop floor. Enter your email below for the entry zone and target.
Horizon: 5–12 Trading Days (Relative-Strength Financials Breakout)
⚡ See Setups #2 & #3 Right Now + Tomorrow's 3 Setups at 8:00 AM ET
Free impersonal market research. Educational levels only — past setups include losing stops and carry real risk of loss.
2. Guru Strategy Screeners, Formula Hub & Head-to-Head Battles
LIVE TAPE